Last reviewed · How we verify
Hydrocodone/Acetaminophen on Extended Release
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate to severe pain requiring opioid therapy.
At a glance
| Generic name | Hydrocodone/Acetaminophen on Extended Release |
|---|---|
| Also known as | ABT-712 |
| Sponsor | Abbott |
| Drug class | Opioid analgesic combination |
| Target | Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Hydrocodone acts as a mu opioid receptor agonist, modulating pain perception and emotional response to pain in the brain and spinal cord. Acetaminophen works through inhibition of cyclooxygenase enzymes, reducing prostaglandin production and providing complementary analgesia. The extended-release formulation delivers both agents over an extended period to maintain sustained pain relief.
Approved indications
- Moderate to severe pain requiring opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Headache
- Respiratory depression
Key clinical trials
- A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine (PHASE4)
- Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) (PHASE3)
- Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) (PHASE3)
- Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocodone/Acetaminophen on Extended Release CI brief — competitive landscape report
- Hydrocodone/Acetaminophen on Extended Release updates RSS · CI watch RSS
- Abbott portfolio CI